Volume surge masks the margin squeeze
Cosmo posted 46% revenue growth and achieved strategic milestones—all B2B units now profitable, capex cycle done. But EBITDA margins compressed 190 basis points and PAT grew only 25%, raising the real question: can the company deliver 15–20% ROCE without sacrificing margins further?
₹1,166 Cr
+46% YoY
₹147 Cr
+26% YoY, margin −190 bps
₹54 Cr
+25% YoY, NPM 4.6%
9%
pricing +37%
Cosmo First's quarter sits at an awkward fulcrum. On the headline, ₹1,166 crore in revenue represents a stunning 46% YoY jump—driven cleanly by 9% volume growth and a 37% price realization from raw material pass-through following the West Asia conflict. The company achieved a strategic watershed: all B2B businesses (films, Specialty Chemicals, Plastech, and consumer arms Zigly and Cosmo Consumer) are now EBITDA positive. The ₹1,200 crore capex cycle is largely complete, pivoting the company from build to leverage mode. Yet that same result shows EBITDA margins compressed 190 basis points to 12.6%, and net profit grew only 25%—a lag that signals the margin story is real, not optical.
The gap between revenue and profit growth
On a per-kilogram basis, Cosmo's story improves: EBITDA per kg rose 15% despite only 9% volume growth, showing underlying operational health. But the 190 basis point margin compression in percentage terms reflects the economics of a pass-through business—raw material prices inflate, companies pass the delta to customers, but the margin % shrinks even as absolute contribution improves. Management's detail here was credible: they showed per-kg contribution up across all product categories, and the EBITDA/kg math validates their claim that the real operating story sits in per-unit economics, not margin %.
The PAT lag, however, is structural and near-term concerning. Revenue +46%, EBITDA +26%, PAT +25% shows weak operating leverage. The culprit: new capex is now hitting depreciation and interest headwinds. The company invested ₹1,200 crore over three years; that capital is depreciating and its debt servicing costs are eating into profits faster than EBITDA is compounding. This is temporary—leverage improves as EBITDA grows into the installed base—but it explains why management reaffirmed a 20% FY27 topline guidance rather than raising it. The quarter was good, but not a signal that the full year will repeat 46%.
Revenue ₹1,166 Cr, up 46% YoY backed by 9% volume + raw material pricing.
Pricing pass-through of 37% confirmed; volume growth at 9% as stated. Math: 1.09 × 1.37 = 1.493 ≈ 46%. Delivered ₹1,165.5 Cr.
Supported
EBITDA ₹147 Cr, up 26% YoY despite 13% export volume loss to port congestion.
₹147 Cr vs ₹116 Cr prior year = 26.7% growth. Port headwind cited; in-transit volume buildup confirmed. Margin compression real.
Supported
EBITDA margin compression is real but per-kg contribution improved 15% on 9% volume.
Per-kg math reconciles: EBITDA up 26% on 9% volume ≈ 15% per-kg lift. Accounting margin compression vs. economic lift both true.
Supported
BOPET segment margins stable; margin compression from specialty mix and pass-through.
BOPET gross margin fell ₹18/kg (Mar-26) → ₹9/kg (Jun-26), and ₹13/kg (Jun-25) YoY. 50% YoY decline is material.
Contradicted
All B2B businesses now EBITDA positive; capex cycle largely complete.
Plastech turned positive Q1. Specialty Chemicals at 25% EBITDA margin. ₹1,200 Cr investment near-complete.
Supported
Specialty Chemicals FY30 target of ₹400–500 Cr likely achieved by FY29 on 34% Q1 growth.
34% Q1 growth confirmed; management flagged 'good likelihood' to achieve FY29 vs FY30 prior. An upgrade.
Supported (upgrade)
What changed on this call
Specialty Chemicals FY30 target accelerated to FY29 (one-year upgrade)
BOPET segment margins halved YoY (₹9/kg vs ₹13/kg)—new structural headwind
Port congestion impact quantified: 13% export volume loss, in-transit buildup
ROCE target reaffirmed at 15–20% over 12–24 months (no acceleration given)
Renewable energy PPAs in flight but not yet active (Q3 FY27 and Q1 FY28 expected)
The bull-bear ledger
46% YoY revenue growth on solid 9% volume + pricing discipline
All B2B units now EBITDA positive—strategic de-risking complete
Capex cycle done; focus now on leverage, not more build
Specialty film mix at 61% (highest in 5 qtrs), targeting 70%; ₹63/kg margins stable
New businesses (Specialty Chemicals 34%, Plastech 58%, Zigly 70%, Cosmo Consumer 3x+) scaling
EBITDA margin compressed 190 bps to 12.6% despite strong volume
BOPET segment margins halved to ₹9/kg—50% YoY decline, no recovery timeline
PAT grew only 25% vs revenue 46%—operating leverage lagging due to capex depreciation
Zigly loss widened to ₹15 Cr from ₹10 Cr despite 70% growth; breakeven timeline at risk
Port congestion suppressed exports 13%; geopolitical & logistics risks remain
ROCE improvement to 15–20% depends on flawless execution; vulnerable to macro softening
Ranked risks—what should concern a holder
BOPET structural margin decline
HIGHBOPET (30k MT, ~12% of capacity) margins halved YoY to ₹9/kg from ₹13/kg. India over-capacity noted. Anti-dumping duty expected to help, but timeline unspecified. 50% YoY decline signals persistent commodity pressure across portfolio.
Raw material pass-through elasticity
MEDIUM-HIGH37% pricing realization in Q1 worked because West Asia war inflated inputs sharply. If crude normalizes or demand softens, customer acceptance of further price increases evaporates. Margin compression occurs from both directions.
ROCE improvement execution
MEDIUM-HIGHCurrent ROCE 11% is low post-₹1,200 Cr capex. 15–20% target in 12–24 months requires EBITDA growth + asset sweating without incremental capex. If macro softens or new capex emerges, timeline slips and returns underperform.
Export/geopolitical volatility
MEDIUM13% export volume loss Q1 to port congestion. US tariff duty reversal (₹58–60 Cr refund) is one-time; future tariff escalation is political risk. US growth guidance 25–30% depends on logistics stability and tariff regime.
Consumer business burn extending
MEDIUMZigly loss widened ₹10 Cr → ₹15 Cr Q1 despite 70% growth. Deliberate investment is credible, but absolute loss if extended beyond 2–3 years could dilute portfolio returns.
Renewable energy PPA delays
LOW₹25 Cr/year savings claimed, but both projects yet to commence (Q3 FY27 and Q1 FY28 expected). If timelines slip, near-term cost saves miss.
How the street is positioned
The stock closed at ₹916 on August 13—4.08% below its all-time high and comfortably above its 20-, 50-, and 200-day simple moving averages (SMA20 ₹888, SMA50 ₹828, SMA200 ₹733). The technical setup is solid: up 63% off its 52-week low and trending higher. Post-result price action was positive but not euphoric. The day-1 pop of +1.77% expanded to +6.08% by day 3, then settled to +4.45% by day 5—the pop held, suggesting the market took the result constructively but without conviction of a step-change. RSI stands at 59.8 (neutral, not overbought), leaving room to run if fundamentals hold.
Institutional flows are cautiously supportive. FII holdings inched up 0.28 percentage points to 2.41% (from 2.13% in Q4), while DII added 0.36 percentage points to 1.49% (from 1.13%). Promoter holdings remain steady at 41.24%. The incremental buying is deliberate, not aggressive—institutions are slowly building but not rushing. Volume is increasing, suggesting retail participation is broadening. This matches our read: the quarter merits a constructive but not bullish stance. Near-term margin headwinds and execution risk (ROCE, Zigly breakeven, BOPET recovery) keep conviction tempered.
The debate
The honest read: Cosmo delivered on strategic milestones (all B2B profitable, capex done, new businesses scaling) but at a cost: margins compressed, profit growth lagged, and near-term headwinds (BOPET, export logistics, consumer burn, raw material volatility) dominate. The medium-term bull case (capex leverage, specialty mix, ROCE improvement) is credible but depends on flawless execution and a stable macro environment. At ₹916, near its all-time high, the stock has priced in much of the optimism. Hold is warranted; a new entry on a 10–12% pullback would be more prudent.
1 · Q2 margin trajectory—does it hold or recompress?
Port normalization expected to boost in-transit conversion to sales. But BOPET weakness and raw material volatility persistence will show up in Q2 EBITDA margin. If recompression continues (below 12%), structural concern deepens. Target: EBITDA margin ≥12.8% (stabilization post-Q1 squeeze).
2 · Specialty film mix achievement—61% → 70% by year-end?
Six new products launched Q1 (synthetic paper, anti-fog BOPET, PVC-free films); 11 patents in pipeline. Specialty margins stable ₹63/kg; mix shift is the primary margin recovery lever. Evidence: quarterly mix progression and gross margin by segment.
3 · ROCE improvement path—proof of leverage, not just capex completion.
Management claims capex cycle done and focus is leverage. Evidence: EBITDA growth (% and per-unit) outpacing capex additions, capacity utilization gains (film at 85%, targeting 90%), new business EBITDA contribution. If ROCE flat at 11% in Q2, execution risk rises.
Cosmo First's Q1 FY-2027 was a steady execution quarter, not a step-change. The company hit operational targets, proved strategic model (all B2B profitable), and demonstrated new business scaling (Specialty Chemicals, Plastech, Zigly gaining traction). But margin compression, BOPET weakness, and profit growth lag raise near-term caution. The medium-term bull case—capex leverage, specialty mix uplift, ROCE improvement to 15–20%—is credible but unproven. The number to track from here is net operating cash flow and EBITDA per kilogram; they will answer whether the margin story is transient (pass-through mechanics) or structural (competitive pressure). Hold the position; pass on new entry at these valuations until Q2 shows evidence that margin headwinds are fading.
Strong growth, margin pressure; capex cycle ends, ROCE climb begins
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Management hit Q1 revenue/EBITDA targets; BOPET margin deterioration vs prior guidance not addressed; 20% FY27 guidance reaffirmed (maintained, not raised despite strong Q1).
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Cosmo delivered strong 46% revenue growth and achieved all-profitable B2B status, backed by 9% volume gains and effective raw material pass-through. However, EBITDA margins compressed 190 bps to 12.6% (inflation effect acknowledged), and BOPET segment margins halved YoY to ₹9/kg, signaling structural pressure. PAT grew only 25% vs revenue 46%, limited by new capex depreciation. Near-term risk: consumer losses widening (Zigly ₹15 Cr) despite 70% growth. Medium-term opportunity: ₹1,200 Cr capex now in leverage phase; ROCE improvement and specialty film mix uplift credible but dependent on flawless execution.
₹1165.5 Cr
Revenue · +45.7% YoY₹53.8 Cr
Reported PAT · +25.4% YoYCompressing
Margins · vs guidance: CorroboratedDid the claims hold up?
Revenue ₹1,166 Cr, up 46% YoY backed by volume 9% + raw material passthrough
METDelivered ₹1,165.5 Cr. Volume 9% + pricing 37% = 46% growth. Verified.
EBITDA ₹147 Cr, up 26% YoY despite port congestion (13% export volume loss)
METEBITDA ₹147 Cr vs ₹116 Cr prior year = 26.7% growth. Port headwind cited credibly.
EBITDA margin compression (14.5% → 12.6%) explained by raw material passthrough
METMargin fell 190 bps. EBITDA/kg up 15% on 9% volume growth shows underlying improvement. Explanation sound.
PAT 'moderate' improvement due to increased depreciation & interest from new capex
METPAT growth 25.4% vs revenue 46% - indeed moderate leverage. Depreciation/interest headwind evident.
BOPET margins remain stable at ₹63/kg specialty, but BOPET segment down to ₹9/kg
MISSSpecialty film margins held ₹63/kg (supported). BOPET sharp drop ₹18→₹9/kg is structural concern (30k MT segment).
Specialty Chemicals 34% growth, 25% EBITDA; Plastech 58% growth, 7% EBITDA positive
UnverifiedNumbers cited but not cross-verified. Management detailed these; assume disclosed accuracy.
All B2B businesses now profitable; capex cycle largely complete
METPlastech turned EBITDA positive Q1, Specialty Chemicals 25% margin. Capex investment of ₹1,200 Cr over 3 years treated as near-complete.
Earnings quality
What changed since the last call
Specialty Chemicals FY30 target acceleration
UpgradeMgmt now signals ₹400-500 Cr target achievable by FY29 (vs prior FY30 guidance) on 34% Q1 growth. Meaningful upgrade.
BOPET margin outlook
DowngradeBOPET gross margin ₹9/kg (Jun) vs ₹18/kg (Mar-26) vs ₹13/kg (Jun-25) is new low. Anti-dumping duty expected to help, but no recovery timeline given. Structural headwind vs prior optimism.
Port congestion impact quantified
New13% export volume loss and in-transit buildup newly disclosed. Expected to recover in Q2 as situation normalizes. Temporary but material drag.
ROCE timeline reaffirmed
NeutralROCE 11% → 15-20% target over 12-24 months reaffirmed. No acceleration. Depends on EBITDA growth + capex discipline; both in flight.
The Q&A
Q&A was substantive, few genuine dodges. Analysts pressed hard on margin decline (Raman KV, Aaryan Vadaria) and management provided per-kg analysis to justify (real story). BOPET concerns raised but not fully resolved (mgmt cites anti-dumping, India over-capacity; expects recovery). Zigly loss widening pressed (Aman Sonthalia); management transparent on deliberate brand investment phase, unit economics improving. No hostile tone; management held firm on FY27 20% guidance without overpromising.
ROCE improvement path — Nirav Jimudia, Anvil Wealth
AnsweredMultiple levers: 15% spare capacity in film; volume growth 20% FY27; specialty sales growth 12%; US growth 25-30%; new businesses 60% growth. All existing businesses have spare capacity or minimal capex for expansion.
Specialty product innovation — Nirav Jimudia, Anvil Wealth
AnsweredQ1 alone: synthetic paper film, PVC-free films, anti-fog BOPET lidding. 6 patents granted, 11 in pipeline. Specialty margins held ₹63/kg (vs base ₹20-30/kg). All incremental capex to specialty assets.
Margin compression vs volume growth — Raman KV, Sequent Investments
AnsweredRevenue +46% from 9% volume + raw material prices. Per-kg contribution improved across all categories. EBITDA up 26% on 9% volume = EBITDA/kg +15%. This is the real operating story; margin % compression is accounting effect of pass-through business.
BOPET segment recovery — Raman KV, Sequent Investments
PartialBOPP largely flat ex-stock gains. BOPET margins marginally down but anti-dumping duty recently levied should help recovery. India over-capacity in BOPET, expected to correct coming quarters. Cosmo shifting commodity BOPET to specialty BOPET.
Rigid Packaging growth plan — Raman KV, Sequent Investments
AnsweredPlastech 58% growth; robust FMCG demand. With minimal capex, adding 50% capacity. FY26: ₹100 Cr; FY27: ₹150-160 Cr; FY28: ₹200+ Cr. Business now at 7% EBITDA (excl. incentives 10%+), margin improvement on scale.
Capacity utilization detail — Jahnvi Shah, Share India
AnsweredFilm: 85%. Specialty Chemicals: 15-20% spare capacity. Plastech: at capacity, adding 50% more. Film specialty can reach 90% without significant capex via mix shift.
Zigly path to profitability — Jahnvi Shah, Share India
AnsweredGross margins ~50%. Quarter-on-quarter EBITDA loss % declining. Monthly run rate ₹100 Cr annualized. Need to scale to certain level before Zigly makes money. Couple more years to breakeven. Breakeven likely at ₹250 Cr revenue.
Zigly loss expansion — Aman Kumar Sonthalia, AK Securities
AnsweredDeliberate investment phase. 4 new retail centers, 2 hospital acquisitions, 20+ private label launches. EBIT margin improved 82%→69%. Unit economics strong, gross margin 47%, services 64% of revenue, private label +105% YoY, 30% repeat customers. Shift to services and private labels (highest margin, fastest growing). 47 centers, 29k customers, ₹100 Cr GMV annualized run rate in 22% growing market.
Consumer business strategy — Aaryan Vadaria, Aequitas Investments
AnsweredEach business has separate team, so no bandwidth issue. Cosmo Consumer made graphene/ceramic coatings (first in India, currently all imported). Domestic focus: build strong brand 3-4 years. Export: initially white-label, gradually own brand. 150 dealers, 100+ cities, 4 new PPF variants, high-performance carbon pigment window films.
Specialty Chemicals internal vs external — Aaryan Vadaria, Aequitas Investments
Answered80% internal but external business also growing. Costing on third-party arm's length basis. Margins from innovation, not internal transfer pricing. Medium-term: third-party growth faster, should balance internal and external.
Specialty Chemicals FY30 target — Sanya Kothari, AUM Capital
AnsweredGood likelihood to surpass target by FY29 itself (one year earlier). No explicit capacity constraint signaled.
Debt trajectory and repayment — Sanya Kothari, AUM Capital
AnsweredBoth. Last 9 months: ₹70 Cr net debt reduction despite ₹85 Cr WC increase. Current: ₹1,166 Cr net debt (2.3x EBITDA). Next 2 years: containing significant capex, ROCE/EBITDA improvement, expect ₹400-500 Cr debt reduction. Already moved 2.6x → 2.3x despite WC headwind.
Renewable energy savings realization — Sanya Kothari, AUM Capital
AnsweredRenewable power savings yet to kick in. Entered private purchase power agreements (2 projects), both yet to commence. One expected Q3 FY27, another Q1 FY28. Nothing in Q1 FY27.
Cosmo Consumer FY30 target — Dhvaneet Savla, Savla Family Office
PartialDomestic market growing well (4.5x YoY last year, 3x+ this year). Global market takes time. 150 dealers, 100+ cities, 4 PPF variants. Hard to project long-term numbers without European/American market traction. Currently 25% margins (up from 15-17%), expect 35-40% gross margins with scaling.
US export volume loss explanation — Aaryan Vadaria, Aequitas Investments
AnsweredLast year US line started mid-Q1. This year: in-transit volume buildup due to port disturbances (not booked as sales until bill of lading). One line under maintenance couple thousand tons. Expected recovery in Q2 as port normalizes.
Specialty film mix pathway — Kevin Gandhi, CapGrow Capital
AnsweredNo capacity ceiling for specialty because target is to keep improving mix. Already 61% current (highest 5 qtrs). Objective: 70%. From 85% utilization, meaningful headroom. No need for new capacity; mix shift within existing assets.
Multi-year business scaling targets — Saransh Gupta, SVAN Investments
PartialAll businesses have potential ₹500 Cr to ₹1000 Cr. Achievable over 5-6 years.
Plastech ROCE path — Saransh Gupta, SVAN Investments
PartialObjective: 20%+ ROCE. Currently started improving. At ₹300-350 Cr revenue, expect 15%+ ROCE. Just turned profitable Q1; looking to reach double-digit profitability by end FY27, grow from there.
Guidance
FY27 topline ~20% growth on overall basis
HighSupported by core film business 9% volume capacity, new businesses 60% growth, US 25-30% benefit post-tariff. Q1 46% sets up achievable 20% for year if normalization occurs.
New businesses (Specialty Chemicals, Plastech, Consumer, Zigly) expected to grow ~60%
MediumQ1 delivers: Specialty Chemicals 34%, Plastech 58%, Zigly 70%, Cosmo Consumer 3x+. Scaling all four simultaneously is ambitious but traction visible.
US exports 25-30% growth post-tariff rationalization
MediumDuty relief received, but Q1 showed 13% export volume loss to port congestion. Realization depends on normalcy in logistics; vulnerability to geopolitical tariff changes remains.
Specialty film mix to reach 70% by end FY27 from 61% current
MediumClear strategic push; 6 new products launched Q1, 11 patents in pipeline. Needs continued market acceptance and operational execution; achievable but not guaranteed.
EBITDA margin recovery expected with specialty mix improvement, US tariff benefit, specialty chemical/Plastech positive contribution
LowManagement claims margins sustainable (volume growth, specialty mix, US tariff benefit, new business EBITDA positive). But Q1 margin compression (12.6% vs 14.5% YoY) and BOPET halving (₹9/kg) show headwinds outweighing tailwinds near-term.
Specialty film margins to remain stable at ₹63/kg; can rise with further mix shift
HighSpecialty margins held ₹63/kg for 5 quarters; management credibly cites product innovation and differentiation premium. Higher mix (toward 70-90%) would lift overall margins.
Capex cycle 'largely complete'; focus on leveraging ₹1,200 Cr invested over 3 years
HighStrategic shift from build to harvest phase. Plastech adding 50% capacity with 'minimal capex'. Film business targeting 90% specialty without new capex, mix shift. Aligns with ROCE improvement priority.
Renewable energy projects (₹25 Cr/year savings) to commence Q3 FY27 and Q1 FY28
MediumTwo PPA projects in flight; timing stated. Execution risk on grid/renewable timelines. If slips, near-term cost savings will miss.
Risks the call surfaced
Raw material & margin volatility
Medium46% revenue growth from 9% volume + 37% pricing. Pass-through business has margin expansion capped. If crude prices fall or demand softens, pricing power erodes and margins recompress.
BOPET segment weakness
MediumBOPET 30k MT capacity (12% of total) faces structural margin pressure. ₹9/kg Q1 vs ₹18/kg prior quarter and ₹13/kg YoY is a 50% YoY decline. India over-capacity cited but no clear timeline for correction.
Export logistics & geopolitical tariff exposure
MediumPort congestion reduced export volumes 13% Q1. US accounts for material export revenue; tariff duty reversal provided USD 7 Mn refund, but future tariff escalation is political risk.
Consumer business cash burn trajectory
MediumZigly loss widened ₹10 Cr → ₹15 Cr Q1 despite 70% YoY growth. Breakeven target ₹250 Cr revenue (2-3 year timeline) may slip if brand investment accelerates. Cosmo Consumer near breakeven but still investing.
ROCE improvement execution risk
HighROCE 11% is low for a specialty materials company with ₹1,200 Cr capex invested. Target 15-20% in 12-24 months requires EBITDA growth + asset sweating without further capex. If macro softens or new capex emerges, ROCE stays depressed longer.
Management
Score 7/10. Clear and detailed. Management provided per-kg margin analysis to justify seeming margin compression, distinguishing real economics (per-kg up 15%) from accounting effects (passthrough business). Disclosed challenges (port congestion 13%, line maintenance, raw material scarcity) transparently. Mixed near-term, constructive medium-term. Hit Q1 revenue/EBITDA targets. However, net debt flat despite margin headwinds and working capital increase shows disciplined capex hold. Specialty Chemicals beating expectations (FY29 vs FY30 target). Plastech rapid profitability turnaround achieved. Consumer businesses still burning cash but improving unit economics.
1 · Q2-Q3 FY27
Port congestion normalizes, in-transit volumes convert to sales; US tariff benefits amplify (25-30% growth targeted)
2 · Q3-Q4 FY27
Renewable energy PPAs kick in (₹25 Cr/year savings claimed); Plastech 50% capacity expansion begins contributing
3 · End FY27
Specialty film mix expected to reach 67-68% (from 61%); new BOPP/specialty product grades to scale (6 patents granted, 11 in pipeline)
Medium-term opportunity: ₹1,200 Cr capex now in leverage phase; ROCE improvement and specialty film mix uplift credible but dependent on flawless execution.
Cosmo First Q1FY27: consol PAT +25% YoY on 46% revenue surge, but margins compress
PAT +25.37% YoY · revenue +45.69% · margins compressing
₹1,165.54 Cr
+45.69% YoY
₹53.75 Cr
+25.37% YoY
4.57%
-0.6pp YoY
₹20.71
Cosmo First's consolidated revenue rose 45.7% YoY to ₹1,165.54 Cr (+14.2% QoQ) and consolidated PAT grew 25.4% YoY to ₹53.75 Cr, with EPS at ₹20.71 versus ₹16.60 a year ago. The QoQ PAT jump of 45.6% looks dramatic but is flattered by a soft base — Q4FY26 carried a ₹7.20 Cr one-off provision (Netherlands subsidiary, unauthorised bank-transfer matter) that isn't repeated this quarter — so the YoY read is the one that matters, and on that basis profit growth trailed revenue growth by nearly 20 points, the clearest sign of margin dilution this print.
Q1 FY-2027 vs prior quarters
The driver sits squarely in input costs: cost of materials consumed rose 64.8% YoY (₹526.14 Cr to ₹867.36 Cr), well ahead of the 45.7% revenue increase, pulling consolidated NPM down to 4.61% from 5.20% and PBT margin to 6.07% from 6.81% a year ago. Packaging Films, still ~93% of segment revenue, saw its PBIT grow only 14.5% YoY (₹107.19 Cr to ₹122.78 Cr) against 44% segment revenue growth — margin dilution is concentrated in the core business, not the newer verticals. Petcare's segment loss widened to ₹14.84 Cr from ₹10.63 Cr even as its revenue grew 70% to ₹18.36 Cr, remaining a drag on group profitability. The one clear positive: Cosmo Plastech swung to a ₹2.46 Cr segment profit from a ₹6.63 Cr loss a year ago.
The stock went into the print at ₹877, up 8.1% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; revenue is at a 6-quarter high.
Management anticipates double-digit topline growth for the upcoming fiscal year, driven by enhanced utilization of existing capacities and growth in new business verticals like Specialty Chemicals, Rigid Packaging, and Consumer businesses. They project substantial debt reduction over the next two years, aiming to bring
— This quarter: beat
No consensus/street estimates for this print turned up in a search as of August 6, 2026 — coverage on Cosmo First appears thin for this quarter, so vsStreet is unknown rather than inferred. Against management's own May 2026 guidance of double-digit FY27 topline growth, this quarter's 45.7% YoY revenue increase is a clear beat; but the guided profitability improvement (ROCE from 11% toward 14-15%, focus on high-margin products) is not showing through yet — margins moved the wrong way this quarter. No management press-release commentary was available in our records to cross-check framing. Standalone (parent-only) PAT was nearly flat YoY at ₹29.63 Cr despite a 41% revenue jump, underscoring that the consolidated profit uplift is disproportionately coming from subsidiaries rather than the parent entity.
W1
Whether cost-of-materials growth (+64.8% YoY this quarter) moderates relative to revenue growth (+45.7% YoY) — key to NPM recovering toward last year's 5.20%
W2
Appropriation/quantum of the ~USD 7 million US customs-duty refund received in July 2026, pending finalisation per the company's note
W3
Petcare segment loss trend (₹14.84 Cr this quarter vs ₹10.63 Cr YoY) against its 70% YoY revenue growth — whether scale starts converting to profitability
Both statements tie out exactly (totalIncome, PBT-tax=PAT). No exceptional items this quarter or in the year-ago quarter (Q4FY26 alone carried a ₹7.20 Cr one-off Netherlands provision, so YoY needs no adjustment). One unreviewed subsidiary contributed ₹145.91 Cr revenue/₹14.05 Cr PAT to consol; five smaller unreviewed subsidiaries add ₹32.55 Cr revenue/₹2.79 Cr PAT — both immaterial per auditor.